Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

Kato, Jun; Kuwabara, Yoshiyuki; Mitani, Masami; Shinoda, Noriyuki; Satō, Atsushi; Toyama, Tatsuya; Mitsui, Akira; Nishiwaki, Takeshi; Moriyama, Satoru; Kudo, Junzo; Fujii, Yoshitaka

doi:10.1002/1097-0215(20010320)95:2<92::aid-ijc1016>3.3.co;2-0

Cited by 40 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, the quantity of Survivin excreted in urine was analyzed, and it was shown that early diagnosis of bladder cancer was possible (29) . Other studies have also shown Survivin expression is related to poor prognosis in breast and colon cancer (30) , acute myelocytic leukemia (31) , lung cancer (28) , epidermal skin cancer (32) , pancreatic cancer (33,34) , and esophageal cancer (35) . However, the clinical significance in uterine cervical cancers has yet to be clarified.…”

Section: Discussionmentioning

confidence: 96%

Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors

Lee¹,

Chang²,

Han³

et al. 2005

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

A novel inhibitor of apoptosis, Survivin, seems to be involved in the critical steps of cancer onset and progression and may be associated with unfavorable clinical outcome. We investigated the expression of Survivin in patients with cervical intraepithelial neoplasia grade 3 (CIN3) and uterine cervical cancer, to determine whether Survivin expression is related to poor prognosis. Fourteen cases of CIN3, 53 cases of invasive uterine cervical squamous cell carcinoma (SCC), and 11 cases of normal control group were analyzed retrospectively. Immunohistochemical staining and Western blot was performed with antihuman Survivin antibody and analyzed with respect to patient outcome. Survivin was significantly expressed in cervical cancer groups compared to the normal control group (P < 0.05). Significant Survivin expression was also noted in cancer patients with lesion size ≥4 cm, lymphovascular invasion, elevated SCC antigen levels, and no response to initial therapy. In more advanced stages, Survivin expression tended to increase but without statistical significance (P = 0.081). No association was noted between Survivin expression and survival rate (P = 0.1011). We conclude that Survivin expression provides some prognostic information regarding uterine cervical cancer, even though it was not correlated with survival. It could represent a possible new prognostic marker of uterine cervical SCC patients.

show abstract

Section: Discussionmentioning

confidence: 96%

Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors

Lee¹,

Chang²,

Han³

et al. 2005

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…In colorectal cancer and breast cancer, patients with survivin-positive tumors had a decreased apoptotic index and worse survival rates than those with survivin-negative tumors [7,8]. In addition, survivin expression correlated with poor prognosis in esophageal cancer and non-small cell lung cancer [9,10]. …”

Section: Discussionmentioning

confidence: 99%

“…In a study using a pancreatic cancer cell line, Asanuma et al reported that survivin may be a radioresistant factor [12], and Kato et al suggested that survivin expression may be a predictive marker for chemotherapy as well as prognostic marker in esophageal cancer in their previous study [9]. We examined the survivin expression in fourteen patients treated with chemotherapy to evaluate the potential of survivin as a predictive marker for chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Survivin expression and its clinical significance in pancreatic cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…94,95,[141][142][143][144][145][146][147][148][149][150][151][152][153][154][155][156][157][158][159][160] A salient feature is that many utilize mRNA expression usually using RT-PCR, others employ Western blotting whilst some employ conventional immunohistochemistry. Using the latter technique, survivin expression is found both in the nucleus and the cytoplasm.…”

Section: Survivinmentioning

confidence: 99%

Apoptosis Genes and Resistance to Cancer Therapy: What Does the Experimental and Clinical Data Tell Us?

Brown

Wilson²

2003

Cancer Biology & Therapy

109

View full text Add to dashboard Cite

The dominant paradigm in cancer treatment is that cancer cells die from the common pathway of apoptosis subsequent to DNA damage by anticancer agents and that cells resistant to apoptosis are resistant to therapy. In this review we trace the logic that brought about this view and discuss whether the clinical and experimental data that have now accumulated over the past decade support the position. We show that there is support for the apoptosis model only for certain malignancies of hematopoietic origin. For the majority of cancers (which are of epithelial origin), even though some may exhibit apoptosis after treatment, there is little or no support for the concept that apoptosis, and the genes that govern it, determine the response to therapy. In general, whether apoptosis matters for overall tumor response depends on how soon after treatment apoptosis occurs. If it occurs early (within 4 to 6 hours after treatment), it is likely to be important for determining the overall response of the cell or tumor. This is the case for some tumors of myeloid and lymphoid origin. On the other hand, if apoptosis occurs long after exposure, 24-48 hrs, and usually after mitosis, then it is unlikely to be the determinant of cytotoxicity, and modifying it is unlikely to affect overall cell killing. This is the situation for most, if not all, tumors of epithelial or mesenchymal origin. What then causes cancer cells to die following treatment with anticancer agents? The evidence from ionizing radiation is clear: DNA damage leading to chromosome breaks. We argue that the situation is similar for most anticancer drugs. Indeed inability to repair the DNA damage produced by these agents, and the levels of the proteins involved in these repair processes, may explain the treatment sensitivity of some cancers. Further clinical studies in this area are needed.

show abstract

Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

Cited by 40 publications

References 0 publications

Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors

Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors

Survivin expression and its clinical significance in pancreatic cancer

Apoptosis Genes and Resistance to Cancer Therapy: What Does the Experimental and Clinical Data Tell Us?

Contact Info

Product

Resources

About